WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000059930) A METHOD OF TREATING CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/059930    International Application No.:    PCT/US2000/008762
Publication Date: 12.10.2000 International Filing Date: 31.03.2000
Chapter 2 Demand Filed:    17.10.2000    
IPC:
A61K 31/495 (2006.01), A61K 31/55 (2006.01), A61K 38/00 (2006.01), A61K 38/12 (2006.01), A61K 45/06 (2006.01)
Applicants: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US) (For All Designated States Except US).
DEFEO-JONES, Deborah [US/US]; (US) (For US Only).
JONES, Raymond, E. [US/US]; (US) (For US Only).
OLIFF, Allen, I. [US/US]; (US) (For US Only)
Inventors: DEFEO-JONES, Deborah; (US).
JONES, Raymond, E.; (US).
OLIFF, Allen, I.; (US)
Common
Representative:
MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US)
Priority Data:
60/127,746 05.04.1999 US
Title (EN) A METHOD OF TREATING CANCER
(FR) UNE METHODE POUR LE TRAITEMENT DU CANCER
Abstract: front page image
(EN)The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is an inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is an inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
(FR)La présente invention concerne des méthodes pour le traitement du cancer mettant en oeuvre un combinaison d'un composé qui est un conjugué d'antigène prostatique spécifique et un composé qui est inhibiteur de la prényle-protéine transférase, lesdites méthodes comprenant l'administration audit mammifère, soit successivement dans n'importe quel ordre ou simultanément, des quantités d'au moins deux agents thérapeutiques choisis dans le groupe constitué d'un composé qui est un conjugué d'antigène prostatique spécifique et un composé qui est inhibiteur de la prényle-protéine transférase. L'invention concerne également des procédés de préparation desdites compositions.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)